Validation of a consumer-grade activity monitor for continuous daily activity monitoring in individuals with multiple sclerosis.

Physical activity accelerometry motor activity multiple sclerosis validation studies as topic (mesh heading)

Journal

Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877

Informations de publication

Date de publication:
Historique:
received: 01 05 2019
revised: 19 10 2019
accepted: 21 10 2019
entrez: 6 12 2019
pubmed: 6 12 2019
medline: 6 12 2019
Statut: epublish

Résumé

Technological advancements of remote-monitoring used in clinical-care and research require validation of model updates. To compare the output of a newer consumer-grade accelerometer to a previous model in people with multiple sclerosis (MS) and to the ActiGraph, a waist-worn device widely used in MS research. Thirty-one individuals with MS participated in a 7-day validation by the Fitbit Flex (Flex), Fitbit Flex-2 (Flex2) and ActiGraph GT3X. Primary outcome was step count. Valid epochs of 5-min block increments, where there was overlap of ≥1 step/min for both devices were compared and summed to give a Bland-Altman plots showed no systematic difference between the Flex and Flex2; mean step-count difference of 25 more steps-per-day more recorded by Flex2 (95% confidence intervals (CI) = 2, 48; Steps from Flex and Flex2 can be used interchangeably. Differences in total step count between ActiGraph and Flex devices can make cross-device comparisons of numerical step-counts challenging particularly for faster walkers.

Sections du résumé

BACKGROUND BACKGROUND
Technological advancements of remote-monitoring used in clinical-care and research require validation of model updates.
OBJECTIVES OBJECTIVE
To compare the output of a newer consumer-grade accelerometer to a previous model in people with multiple sclerosis (MS) and to the ActiGraph, a waist-worn device widely used in MS research.
METHODS METHODS
Thirty-one individuals with MS participated in a 7-day validation by the Fitbit Flex (Flex), Fitbit Flex-2 (Flex2) and ActiGraph GT3X. Primary outcome was step count. Valid epochs of 5-min block increments, where there was overlap of ≥1 step/min for both devices were compared and summed to give a
RESULTS RESULTS
Bland-Altman plots showed no systematic difference between the Flex and Flex2; mean step-count difference of 25 more steps-per-day more recorded by Flex2 (95% confidence intervals (CI) = 2, 48;
CONCLUSIONS CONCLUSIONS
Steps from Flex and Flex2 can be used interchangeably. Differences in total step count between ActiGraph and Flex devices can make cross-device comparisons of numerical step-counts challenging particularly for faster walkers.

Identifiants

pubmed: 31803492
doi: 10.1177/2055217319888660
pii: 10.1177_2055217319888660
pmc: PMC6876176
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2055217319888660

Informations de copyright

© The Author(s) 2019.

Références

PLoS One. 2014 Apr 08;9(4):e93511
pubmed: 24714028
J Sports Sci. 2018 Jul;36(13):1502-1507
pubmed: 29099649
Arch Phys Med Rehabil. 2009 Oct;90(10):1778-84
pubmed: 19801071
Arch Phys Med Rehabil. 2013 Aug;94(8):1534-9
pubmed: 23419331
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Disabil Health J. 2016 Apr;9(2):320-3
pubmed: 26905972
Br J Anaesth. 2007 Sep;99(3):309-11
pubmed: 17702826
Prog Cardiovasc Dis. 2011 May-Jun;53(6):397-403
pubmed: 21545925
Int J Hyperthermia. 2009 Feb;25(1):34-40
pubmed: 19219698
BMC Res Notes. 2014 Dec 23;7:952
pubmed: 25539733
JAMA Netw Open. 2019 Mar 1;2(3):e190570
pubmed: 30874777
J Med Life. 2016 Jan-Mar;9(1):101-105
pubmed: 27974923
Adapt Phys Activ Q. 2007 Jul;24(3):245-53
pubmed: 17916920
J Biopharm Stat. 2007;17(4):571-82
pubmed: 17613642
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
J Neurol. 2017 Feb;264(2):316-326
pubmed: 27896433
Mult Scler J Exp Transl Clin. 2016 Mar 4;2:2055217316634754
pubmed: 28607720
J Sci Med Sport. 2014 Sep;17(5):496-500
pubmed: 24268570
J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):884-8
pubmed: 15146006
PLoS One. 2016 Apr 28;11(4):e0154335
pubmed: 27124611
Int J Sports Med. 2013 Nov;34(11):975-82
pubmed: 23700330
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Med Eng Phys. 2012 Jun;34(5):590-7
pubmed: 21968005
Am J Phys Med Rehabil. 2011 May;90(5):372-9
pubmed: 21389842
Eur J Prev Cardiol. 2016 Sep;23(14):1476-85
pubmed: 26907794
Med Sci Sports Exerc. 2011 Feb;43(2):357-64
pubmed: 20581716
Int J Cardiol. 2015 Apr 15;185:138-40
pubmed: 25795203
Eur Neurol. 2014;71(3-4):196-202
pubmed: 24457548
Expert Rev Neurother. 2012 Sep;12(9):1079-88
pubmed: 23039387
J Neurol Phys Ther. 2015 Apr;39(2):103-10
pubmed: 25742375
Arch Phys Med Rehabil. 2013 Dec;94(12):2342-8
pubmed: 23906692
PLoS One. 2013 Sep 04;8(9):e73247
pubmed: 24023843

Auteurs

Valerie J Block (VJ)

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA.

Chao Zhao (C)

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA.

Jill A Hollenbach (JA)

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA.

Jeffrey E Olgin (JE)

Department of Epidemiology and Biostatistics, University of California San Francisco, USA.

Gregory M Marcus (GM)

Department of Epidemiology and Biostatistics, University of California San Francisco, USA.

Mark J Pletcher (MJ)

Department of Medicine, University of California San Francisco, USA.

Roland Henry (R)

Weill Institute for Neurosciences, University of California San Francisco, USA.

Jeffrey M Gelfand (JM)

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA.

Bruce Ac Cree (BA)

Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA.

Classifications MeSH